Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.
Actively Recruiting
Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.
Actively Recruiting
Researchers are studying adults living with autoimmune neurological disorders, starting with myasthenia gravis MG, to understand how symptoms, daily functioning, and quality of life change over time. The study also examines treatments participants use and the challenges they face, such as side effects, treatment burden, missed doses, and access to care. This observational registry aims to collect long-term data to better understand MG and improve future research and care. Participants join the registry remotely through a secure website or mobile app and complete an enrollment survey about their MG diagnosis and history. They then complete monthly online questionnaires about their symptoms, treatments, and quality of life. The registry collects participant-reported information on antibody testing, chest imaging, thymus findings, thymectomy, and healthcare use. Sharing medical records is optional, and diagnosis confirmation may be done through documents or healthcare provider authorization. Throughout the study, participants provide information on symptom severity and treatment use via standardized questionnaires like the Myasthenia Gravis Activities of Daily Living profile MG-ADL and the Myasthenia Gravis Quality of Life questionnaire MG-QOL15r. The registry includes data quality checks and may contact participants for clarifications. Study data is securely stored with privacy protections, and the registry plans to continue for many years, updating research questions and questionnaires as needed. Participants can expect remote monthly surveys and ongoing monitoring up to 10 years.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Healthy Volunteer
Researchers are studying the safety and effectiveness of several 1% tolnaftate formulations delivered through new stick-based applicators for treating tinea pedis, also known as athletes foot. This phase 2 clinical trial focuses on individuals diagnosed with potassium hydroxide KOH-positive tinea pedis to evaluate how well these topical treatments work and how safe they are to use. Participants will receive one of three different formulations of 1% tolnaftate in a stick applicator Formula A, Formula B, or Formula C. All three formulations are applied topically to the affected foot area twice daily for four weeks. The study does not use random assignment or blinding, and each group will use their assigned formulation throughout the treatment period. During the study, participants will be monitored for a complete cure at week 4, which is the primary outcome measure. They will need to comply with the study protocol and be available for the entire study duration. Safety and response to treatment will be assessed by clinical evaluations and microscopy confirmation. The total participation time includes the 4-week treatment and necessary follow-up visits to check for effectiveness and any side effects.